Albuquerque, NM, April 02, 2014 --(PR.com
)-- "We welcome the addition of Dr. Garcha," noted Sheldon K. Jordan, PhD, CEO. Dr. Garcha holds an Honor’s BSC in Cell Biology and MSc. in Zoology from Western University, and a PhD. in Cellular & Physiological Sciences from the University of British Columbia. During the course of Dr. Garcha’s research, he has developed a high throughput in vitro drug screening platform that has facilitated the discovery of numerous therapeutic agents that promote cartilage development and the molecular mechanisms underpinning regeneration. Continuing in the pursuit of therapeutic discovery, during his Post-doctoral work at the University of Toronto, Dr. Garcha derived patient-specific induced pluripotent stem cells (iPSCs) for the development of personalized cell based models of disease for several musculoskeletal disorders in addition to a rare women’s lung cancer (lymphangioleiomyomatosis). Recently, Dr. Garcha served as a director of an R&D platform in a Canadian company focused on the commercialization of technologies and translation of intellectual property for regenerative medicine applications. It is expected that his diverse experience will benefit Peptineo’s development and commercialization efforts going forward.